The seven (7) peptide bulk drug substances expected to be considered by the PCAC in July, together with the uses identified for evaluation, are: July 23, 2026 : BPC-157 (free base and acetate): ulcerative colitis KPV (free base and acetate): wound healing and inflammatory conditions Thymosin Beta-4, Fragment (LKKTETQ)(TB-500) (free base and acetate): wound healing MOTs-C (free base and acetate): obesity and osteoporosis July 24, 2026 : Emideltide (DSIP) (free base and acetate): opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate): cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate): insomnia The peptide substances scheduled for consideration at the July 23-24, 2026, PCAC meeting are among those identified for removal from Category 2
Function as a helpful tool for peptide-mediated cytoprotection, sports medicine models, and regenerative biology
When fully dissociated, cells were centrifuged (230 g , 3 min) and the cell pellet resuspended and diluted to approximately 2.5E06 cells/mL in Recovery TM Cell Culture Freezing Medium (Gibco, #12648-010)
Some studies suggest potential roles in angiogenesis, collagen-related repair processes, inflammatory signaling, and protection of different tissue types
